Kimberly A Chapman,Farid Ullah,Zachary A Yahiku,Sri Varsha Kodiparthi,Georgios Kellaris,Sandrina P Correia,Tommy Stödberg,Christalena Sofokleous,Nikolaos M Marinakis,Helena Fryssira,Eirini Tsoutsou,Jan Traeger-Synodinos,Andrea Accogli,Vincenzo Salpietro,Pasquale Striano,Seth I Berger,Kelvin W Pond,Suman Sirimulla,Erica E Davis,Martha Rc Bhattacharya

Abstract:Transmembrane protein 184B (TMEM184B) is an endosomal 7-pass transmembrane protein with evolutionarily conserved roles in synaptic structure and axon degeneration. We report six pediatric patients who have de novo heterozygous variants in TMEM184B. All individuals harbor rare missense or mRNA splicing changes and have neurodevelopmental deficits including intellectual disability, corpus callosum hypoplasia, seizures, and/or microcephaly. TMEM184B is predicted to contain a pore domain, wherein many human disease-associated variants cluster. Structural modeling suggests that all missense variants alter TMEM184B protein stability. To understand the contribution of TMEM184B to neural development in vivo, we suppressed the TMEM184B ortholog in zebrafish and observed microcephaly and reduced anterior commissural neurons, aligning with patient symptoms. Ectopic TMEM184B expression resulted in dominant effects for K184E and G162R. However, in vivo complementation studies demonstrate that all other variants tested result in diminished protein function and indicate a haploinsufficiency basis for disease. Expression of K184E and other variants increased apoptosis in cell lines and altered nuclear localization of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis, suggesting disrupted nutrient signaling pathways. Together, our data indicate that TMEM184B variants cause cellular metabolic disruption likely through divergent molecular effects that all result in abnormal neural development.

Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome via alteration of metabolic signaling